Genotoxicity

Genotoxicity refers to the ability of chemical or biological agents to damage genetic material, causing mutations, chromosomal breaks, or DNA rearrangements that may lead to cancer or heritable defects. Genotoxic effects include point mutations, deletions, insertions, and structural chromosomal alterations resulting from direct DNA interaction or interference with replication and repair processes.

The biopharmaceutical industry rigorously evaluates genotoxicity during preclinical development to ensure patient safety. Standard testing includes bacterial reverse mutation assays, in vitro chromosomal aberration tests, and in vivo micronucleus studies. Regulatory agencies require genotoxicity assessment for small molecules and certain impurities to minimise carcinogenic risk. Positive findings may necessitate structural modification, dose limitation, or enhanced clinical monitoring. As regulatory expectations evolve, genotoxicity testing remains a critical component of safety evaluation supporting informed risk-benefit decisions.